Investors looking for a higher risk emerging markets stock could do a lot worse than Hutchison China MediTech, if recent analyst reports are to be believed.

This AIM listed company has seen its share price soar over the past 12 months as a result of product development and global expansion.

The subsidiary business of Hutchison Whampoa (better known for its historical links with mobile phone company Orange) is a holding company of a pharmaceutical and healthcare group based primarily in China and is ideally placed to take advantage of the predicted ongoing growth in the Chinese healthcare market.

Tipsters’ New Year outlook reports highlight the company’s growth potential as a result of its three business divisions stretching from traditional Chinese remedies to western prescription drugs and branded consumer products. Among them is The Share Centre’s Nick Raynor. 

He says, ‘We like HCM because of its exposure to China and its huge potential for growth in the healthcare market. Over the past six months HCM’s share price has increased by over 200 per cent.

‘Although growth has slowed over the past three months we believe there is still plenty of potential to be had. As such, we rate HCM as a higher risk investment.’